GEN-MKT-18-7897-A
Feb 12, 2025 | Blogs, Discovery, Echo® MS+ system, Pharma, QA/QC | 0 comments
Read time: 2 minutes
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
To achieve this drug discovery assays require speed and accuracy, but often scientists must compromise on one of these requirements to cope with the thousands of samples that need to be analyzed.
The Echo® MS+ system allows pharmaceutical companies to make data-driven decisions early in the drug discovery process, saving time and money, and potentially getting their drug to market faster than with more traditional approaches. Common analytical techniques such as LC-MS or fluorescence are limited by either sample throughput or accuracy of results.
Learn more >
The Echo® MS+ system uses acoustic ejection mass spectrometry (AEMS) technology. Samples are placed into a compatible well plate which is held in the Echo® MS+ system’s autosampler. Here sound energy is applied to the bottom of each well individually. The sound energy causes reproducible droplets to be ejected from the well for capture in a carrier solvent of the OPI for dilution and transfer to the mass spectrometer’s source. From this point, the diluted sample is ionized using conventional electrospray ionization, ready for detection.
Watch video >
Pesticides are widely used in agriculture to protect crops and maintain yield, but their presence in food must be carefully monitored. To safeguard consumers, regulatory authorities worldwide set maximum residue limits (MRLs), often at very low concentrations and across a wide range of compound classes.
Explore why capillary electrophoresis remains essential for high resolution, confident analytics across modern biopharma modalities, from proteins to mRNA and gene therapies
Capillary electrophoresis (CE) is not confined to a single point in the drug development lifecycle. Its value comes from the ability to deliver high‑resolution, reproducible separations that remain relevant as analytical questions evolve, from early discovery through late‑stage development and lot release.
Posted by
You must be logged in to post a comment.
Share this post with your network